To elucidate the possible role of NF-kB in mouse skin carcinogenesis we studied the expression of p50 (NFkB1), p52 (NF-kB2), p65 (RelA) and IkB-a inhibitor as well as kB-binding activity in adult SENCAR mouse skin, skin papillomas, and squamous cell carcinomas (SCC) generated by a two-stage carcinogenesis protocol. We found that in normal epidermis all of the above proteins were mostly expressed in the cytoplasm of basal cells. Western blot analysis revealed a dramatic increase of p50 and p52 expression in mouse skin tumors starting from the middle stage of promotion. We also found that the level of IkB-a protein in many late papillomas and SCC was lower than in normal epidermis. Results of EMSA showed an increase in kB-binding activity in mouse skin tumors and suggested that p50 is the major component of constitutive kB-binding complexes in normal epidermis and in tumors. It has been shown that nuclear IkB protein Bcl-3 is able to increase p50/p50 homodimer binding to the dierent kB sites in mouse thymocytes. Our ®nding on Bcl-3 overexpression in late papillomas and SCC could explain the selective increase of p50-related kB-binding in mouse skin tumors. Thus, our results strongly suggest the important role of p50 in skin carcinogenesis.
Introduction
The inducible NF-kB factors regulate the transcription of a wide variety of cellular and viral genes. The active NF-kB complex is either a homo-or heterodimer composed of proteins from NF-kB/Rel family. Five members of the mammalian NF-kB/Rel family have currently been cloned and characterized; they encode the proteins p50 (NF-kB1), p52 (NF-kB2), p65 (RelA), RelB, and c-Rel (reviewed in Baldwin, 1996; Gilmore et al., 1996) . These structurally related interacting proteins bind as dimers to kB motif sequences found in the promoter and enhancer regions of the genes. The anity of speci®c NF-kB factors for dierent DNA kB sites is determined by the dierent combinations of NF-kB/Rel proteins in dimers (reviewed in Matthews and Hay, 1995; Baldwin, 1996) .
The primary level of control for NF-kB is mediated through the cytoplasmic inhibitory proteins called IkB (Baldwin, 1996; Whiteside and Israel, 1997) . The IkB family include several IkB proteins and proteins p105 and p100 encoded by nf-kb1 and nf-kb2 genes respectively (Gilmore et al., 1996; Whiteside and Israel, 1997) . Previously p100 and p105 were thought to be precursors of NF-kB proteins p52 and p50 (Gilmore et al., 1996; Whiteside and Israel, 1997) , however, some recent data indicate that p50 and p105 are generated independently through unique cotranslational processing . When nuclear localization sequences of NF-kB/Rel are covered by IkB, they are retained in the cytoplasm and do not function as active transcription factors (reviewed in Baldwin, 1996; Matthews and Hay, 1995; Siebenlist et al., 1994) . Upon stimulation, the IkB proteins are phosphorylated and rapidly degraded through ubiquitin-dependent proteolysis releasing NF-kB to translocate to the nucleus and to activate the expression of target genes (Whiteside and Israel, 1997) . The function of the Bcl-3 protein, even though it is structurally similar to other IkB proteins, appears to be dierent. In some experimental systems Bcl-3 was shown to selectively increase p50/p50 homodimer binding to the dierent kB sites thereby acting as coactivator of NFkB (Caamano et al., 1996) .
Several lines of evidence suggest that proteins from the NF-kB and IkB families are involved in carcinogenesis. NF-kB controls the expression of several growth factors, oncogenes and tumor-suppressor genes (c-myc, p53), genes encoding cell adhesion proteins (ICAM-1, ELAM-1, VCAM-1) and proteases of the extracellular matrix (Gilmore et al., 1996) . Thus, NF-kB may play a critical role in carcinogenesis through either the alteration of cell growth or disruption of cell adhesion. NF-kB is activated by various stimuli, including growth factors, physical carcinogens and tumor promoters (reviewed in Matthews and Hay, 1995) . Retroviruses that contain v-Rel are highly oncogenic and cause lymphomas in birds (Bose, 1992) . When overexpressed in transgenic mice v-Rel also produced lymphomas (Carrasco et al., 1996) . Mutant c-Rel was shown to transform cells in vitro (Sylla and Temin, 1986) . The genes encoding cRel, p65, NF-kB1, NF-kB2, and Bcl-3 are located at sites of recurrent translocations and genomic rearrangements in leukemias and lymphomas (reviewed in Dejardin et al., 1995; Gilmore et al., 1996; Matthews and Hay, 1995) . The increase in expression of either p50 or p52 was found in non-small cell lung carcinomas and human breast carcinomas (Dejardin et al., 1995; Mukhopadhyay et al., 1995) as well as in some colon, lung, and breast tumor cell lines (Bours et al., 1994; Dejardin et al., 1995; Mukhopadhyay et al., 1995) .
Among a variety of experimental models for multistage carcinogenesis, the SENCAR mouse skin carcinogenesis model has led to the identi®cation of many cellular and molecular events that are speci®c and critical for each stage (Slaga et al., 1995) . There are several compelling reasons to assume that NF-kB could play an important role in mouse skin carcinogenesis and may be involved in keratinocyte transformation. Epidermal in¯ammation and hyperplasia play a critical role in skin tumor promotion (Slaga et al., 1996) , and NF-kB is a well-known mediator of the in¯ammatory response in many systems (Karin, 1998) . Skin tumor promoters such as phorbol esters and okadaic acid are strong inducers of NF-kB in dierent cells including keratinocyte cell cultures (Baeuerle, 1991; Hansen et al., 1992; Manna et al., 1998; Tobin et al., 1996; Traenckner et al., 1995) . Further, the elevated expression and activation of the Ha-ras oncogene by point mutations are speci®c for more than 90% of mouse skin tumors induced by DMBA/TPA protocol used in our experiments (Binder et al., 1998; Slaga et al., 1995) . Recent data on IkB-a degradation in cells transfected with activated v-Ha-ras or mutated c-Ha-ras (point mutation in codon 61) Figure 1 Immunolocalization of NF-kB/IkB proteins in SENCAR mouse skin. Dorsal skin cryosections from 8 ± 10 week old SENCAR mice were stained with the anti-p50 (a), anti-p52 (b), anti-p65 (c), anti-IkB-a (d) primary antibodies, and as a negative control with FITC-conjugated goat anti-rabbit IgG only (e) and analysed by¯uorescent microscopy. 6300 imply a role for Ha-ras in NF-kB activation (Folgueira et al., 1996) . In addition, dominant negative forms of Ha-Ras decreased NF-kB activation by inducers in dierent cells (Folgueira et al., 1996; Koong et al., 1994) . In spite of all these data, our knowledge about the alterations in the expression and function of NFkB transcription factors during skin carcinogenesis is still very limited. As the ®rst step to elucidate the possible role of NF-kB factors in mouse skin carcinogenesis, we studied the expression of p50, p52, p65 and the inhibitor IkB-a as well as kB-binding activity in SENCAR mouse skin and in mouse skin tumors induced by the standard DMBA/TPA skin carcinogenesis protocol.
Results

Increased expression of p50 and p52 in mouse skin tumors
In the present study we focused on the expression of components of classical NF-kB factor, proteins p50 and p65 and its inhibitor, IkB-a in mouse skin tumors during sequential stages of mouse skin carcinogenesis. We also studied the changes in the expression pattern of p52 protein known to be overexpressed in some other solid tumors and transformed cell lines (Bours et al., 1994; Dejardin et al., 1995; Mukhopadhyay et al., 1995) .
Results of Western blot analysis and immunostaining revealed that adult SENCAR mouse epidermis expressed p50, p52, p65, and IkB-a (Figures 1 and 2 ). In addition, immunostaining indicated that in normal skin all these proteins are mostly localized in cytoplasm of basal keratinocytes (Figure 1) .
Western blot analysis of more than 20 tumor samples (papillomas at 10 ± 40 weeks of promotion and SCC) showed a strong increase of p50 expression in all tumors starting after 18 ± 20 weeks of TPA applications (Figure 2 ). We should mention that even though we have used for Western blot analysis several dierent p50 antibodies, including antibodies against C-terminus, N-terminus, and NLS of p50, we have not detected p50 precursor, protein p105 either in skin or in skin tumors. However this p105 protein is easily detected by dierent antibodies in lymphoid tissues (Weih et al., 1994) . Using a selected set of tumors, we also found a signi®cant increase in p52 expression in some papillomas and SCC (Figure 2 ). This was accompanied by a moderate decrease in IkB-a protein expression in late papillomas and SCC. The expression of p65 was not changed in tumors in comparison with skin.
Constitutive activation of NF-kB transcription factors in mouse skin tumors
To study whether signi®cant changes in NF-kB protein levels aect NF-kB function, we performed EMSA analysis using whole-cell and nuclear protein extracts and kB-oligonucleotide corresponding to a palindromic binding site known for its uniformly high anity for dierent NF-kB homo-and hetero-dimers (Dobrzanski et al., 1993) . We found a strong increase of kB-binding in 11 out of 13 skin tumors including papillomas at 20 ± 46 weeks of promotion and SCC (Figures 3 and  4a) . However, the level of kB-binding in two other papillomas at 30 weeks of promotion did not increase (Figure 4a , last lane and data not shown) even though the level of p50 evaluated by Western blotting in those tumors was also higher than in epidermis ( Figure 6a , lanes 3 and 6). Figure 2 Western blot analysis of NF-kB and IkB-a expression in SENCAR mouse skin tumors. Western blots containing wholecell proteins (10 mg/lane) from papillomas at 10 ± 30 weeks of promotion and squamous cell carcinomas (SCC) were probed for expression of p50, p52, p65, and IkB-a. Epidermis from untreated animal (E) was used as a control Figure 3 Analysis of kB-binding activity in mouse skin tumors. Electrophoretic mobility shift assay (EMSA) was performed by incubating whole-cell protein extracts (10 mg) from epidermis (E), papillomas at 20 ± 40 weeks of promotion, and squamous cell carcinomas (SCC) with a labeled kB-oligonucleotide EMSA revealed the same two major kB-binding complexes in whole-cell and in nuclear protein extracts from epidermis, and skin tumors. Analysis of nuclear kB-binding complexes was done in EMSA experiments using anti-p50 and anti-p65 antibodies (Figure 4b ,c). Incubation of nuclear extracts from both epidermis and skin tumors with anti-p50 antibody removed both bands, while incubation of nuclear extracts with antip65 antibody removed only the upper band. Incubation of extracts with anti-p52, anti-c-Rel, and anti-RelB antibodies did not aect complex mobility (data not shown). These results suggest that complexes both in normal and transformed keratinocytes are composed of p50/p65 and p50/p50 dimers and clearly indicate that p50 is the major component of all kB-binding complexes in keratinocytes. Surprisingly, the increase in p52 protein expression in tumors ( Figure 2 ) did not result in the participation of this NF-kB protein in DNA binding (data not shown).
To ®nd out whether any changes in transcriptional activity of NF-kB occurred in tumors, we studied the transcriptional activation of endogenous NF-kBresponsive genes. Due to the complex regulation of gene transcription and the presence of numerous binding sites for dierent transcription factors in the promoter region of each endogenous gene, only some of NF-kB-responsive genes should be activated in tumors. However, we hoped that Northern blot analysis of nf-kb1 and ikb-a genes transcription could provide useful information about transcriptional activity of NF-kB in tumors. It is known that these genes are tightly regulated by NF-kB in dierent cells and contain multiple kB sites in the promoter region (Le Bail et al., 1993; Ten et al., 1992) . Northern blot analysis of more than 20 tumor samples revealed that in 75% of benign and malignant mouse skin tumors the level of nf-kb1 and ikb-a mRNAs were higher than in normal epidermis ( Figure 5) . Thus, the increase of these endogenous genes expression on the mRNA level suggests that not only kB-binding activity but also transactivation activity of NF-kB factors was increased in transformed keratinocytes. It is important to mention that the increase of nf-kb1 mRNA and p50 protein levels coincided in time, being signi®cantly higher in tumors than in normal epidermis starting from the middle of the promotion stage (Figures 2 and 5) . We are aware that data regarding the increase of IkB-a mRNA levels are inconsistent with the decrease of IkB-a protein levels in tumors (Figure 2) . One possible explanation could be an increased turnover of IkB-a protein through speci®c (phosphorylation and ubiquitination) or nonspeci®c pathways.
Localization of p50 in tumors
The most important conclusions from the experiments described above are that p50 is the major Figure 4 Identi®cation of nuclear kB-binding complexes in mouse epidermis and skin tumors. (a) EMSA was performed by incubating nuclear extracts (3 mg) from untreated mouse epidermis (E) and papillomas at 18-, 28-and 30-weeks of promotion with a labeled kB-oligonucleotide. (b) Nuclear extract (3 mg) from untreated mouse epidermis was incubated with the indicated antibodies before adding the labeled kB-oligonucleotide. P.I.: Preimmune serum. (c) Nuclear extract (3 mg) from mouse skin papilloma after 18 weeks of promotion was analysed by EMSA as described above. Composition of the dimers is indicated at the right Figure 5 Northern blot analysis of nf-kb1 and ikb-a gene expression in SENCAR mouse skin tumors. Northern blots containing total RNA (10 mg/lane) from papillomas at 20 ± 30 weeks of promotion and squamous cell carcinomas (SCC) were probed for expression of nf-kb1 and ikb-a. The membranes were also hybridized with a 7S RNA probe. Epidermis from untreated animal (E) was used as a control. The experiment was repeated with dierent sets of tumors and dierent samples of epidermis. Figure shows the result of representative Northern blot component of kB-binding complexes in epidermis and tumors, and that this protein is overexpressed starting from the middle stages of skin carcinogenesis. As shown in Figure 1a , p50 is preferentially localized in the cytoplasm of normal keratinocytes in mouse skin. To better understand the mechanism of prominent NF-kB activation related to p50 in mouse skin tumors, we studied p50 localization in transformed keratinocytes by Western blotting and found that p50 was presented mostly in the cytoplasm of these cells (Figure 6a ). These data con®rmed the increased p50 expression in tumors shown in Figure 2 and indicated that the amount of p50 was increased both in cytosol and nuclei (even though to a lesser extent) of keratinocytes in tumors in comparison to corresponding protein fractions in skin.
We extended the analysis of p50 localization in tumors using indirect immunostaining. In papillomas, as shown in Figure 6b , p50 was strongly expressed mostly in the epithelial component of the tumors, primarily in less dierentiated cells morphologically similar to the basal and suprabasal cells in skin. p50 was mostly localized in the cytoplasm but also in nuclei of transformed keratinocytes. These data are in agreement with our results obtained by Western blotting ( Figure  6a ) and EMSA (Figure 4 ) indicating accumulation and possible functional activation of nuclear p50 during skin carcinogenesis.
Possible role of Bcl-3 in activation of p-50-related NF-kB activity during skin carcinogenesis Bcl-3 protein, even though it has structural similarities with other IkB proteins, possesses speci®c functional features, and under certain circumstances is able to increase selectively p50/p50 homodimer binding to the dierent kB sites (Caamano et al., 1996) . These data suggest that Bcl-3 could play an important role in modulation of kB-binding and NF-kB function.
Using selected set of mouse skin tumors we found that expression of Bcl-3 was increased in late papillomas and SCC (Figure 7 ). In addition, in vitro incubation of whole-cell protein extracts with alkaline phosphatase followed by Western blotting indicated Figure 6 p50 localization in SENCAR mouse skin tumors. (a) Western blot analysis of p50. Western blots containing 20 mg/lane of cytosolic and nuclear proteins from epidermis and papillomas were probed using p50 antibody. Lanes 1 and 4 ± epidermis (E); lanes 2 and 5 ± papilloma at 18 weeks of promotion; lanes 3 and 6 ± papilloma at 30 weeks of promotion. Note that membrane with nuclear proteins was exposed signi®cantly longer due to the low level of p50 signal in nuclear fraction. (b,c) Immunolocalization of p50. Cryosection of papilloma at 18 weeks of promotion was stained with p50 antibody (b), and as a negative control with FITCconjugated goat anti-rabbit IgG only (c) and analysed by¯uorescent microscopy. 6300 Figure 7 Expression of Bcl-3 in benign and malignant mouse skin tumors. Western blots containing whole-cell proteins (10 mg/ lane) from papillomas and squamous cell carcinomas (SCC) were probed for Bcl-3 expression. Epidermis from untreated animal (E) was used as a control that Bcl-3 is heavily phosphorylated in both normal and transformed mouse keratinocytes (data not shown).
Discussion
To provide an insight into the importance of NF-kB transcription factors in skin carcinogenesis, we focused our research on the expression changes of the components of the classical NF-kB/IkB complex: p65, p50 and IkB-a proteins as well as on p52 protein which has been reported to be overexpressed in some human tumors as well as in some tumorigenic cell lines (Bours et al., 1994; Dejardin et al., 1995; Mukhopadhyay et al., 1995) . The in vivo studies described here revealed a dramatic increase in p50 expression on both mRNA and protein levels starting from the middle of the promotion stage of mouse skin carcinogenesis. In addition, we found an increase of p52 protein expression and a moderate decrease in the expression of IkB-a protein in late papillomas and SCC. EMSA results clearly indicate that kB-binding in mouse skin tumors was much higher than in normal epidermis. Analysis of NF-kB complexes bound to DNA indicated that in mouse epidermis as well as in skin tumors p50 appears to be the major component especially in the form of p50/p50 homodimers. Thus, our data on the selective increase of p50 and p52 in skin tumors are in line with the results on p50 and p52 overexpression in other solid tumors (Bours et al., 1994; Dejardin et al., 1995; Mukhopadhyay et al., 1995) . Changes in p65 expression during mouse skin carcinogenesis were not detected. In addition, our preliminary data indicate that the expression of RelB and cRel proteins remained unchanged in skin tumors (data not shown).
In contrast to p65, RelB and c-Rel proteins, which have relatively long transactivation domains, p50 and p52 have short C-termini (reviewed in Matthews and Hay, 1995) . This possibly results in a weaker potential to activate gene transcription (reviewed in Matthews and Hay, 1995) . The biological role of p50 homodimers appears to be ambiguous. In some experimental systems p50/p50 homodimers activated transcription from promoters with speci®c kB sites (Collart et al., 1990; Fujita et al., 1992 Fujita et al., , 1993 Kretzschmar et al., 1992; Schouten et al., 1995; Ten et al., 1992) . In other experimental systems these homodimers were unable to activate gene transcription (Beg et al., 1992; Franzoso et al., 1992; Kang et al., 1992; Plaksin et al., 1993; Schmitz and Baeuerle, 1991) . It seems that p50/p50 displays high anity binding for many distinct kB motifs but provides a strong transcriptional activation only when adopting a speci®c conformation induced by certain kB motifs but not others (Fujita et al., 1992) . Interestingly, there are some data that p50/p50 homodimers possessing a high anity to speci®c kB sites may actually inhibit transcriptional activation of genes by NF-kB factors more potent as transactivators than p50/p50 (reviewed in Baldwin, 1996) . Thus, our data on the increase of p50 and p52 expression and the increase of p50-related kB-binding in transformed keratinocytes, suggest that only restricted and speci®c set of kBresponsive genes is under transcription in mouse skin tumors and the transcription of some other kBresponsive genes could be actually inhibited.
Among genes positively regulated by p50/p50 homodimers are TNF-alpha, major histocompatibility complex (MHC) class I genes, as well as its own gene nf-kb1 which encodes p50 as well as the inhibitor protein p105 (Collart et al., 1990; Schouten et al., 1995; Ten et al., 1992) . There are also data indicating that p50/p50 binds with high anity to certain kB sites in the promoter region of ikb-a and nf-kb2 genes (Le Bail et al., 1993; Liptay et al., 1994) . Our data obtained by Northern blot analysis indeed suggest that transcription of the nf-kb1 and ikb-a genes is increased in mouse skin tumors.
Although in general NF-kB factors positively regulate proliferation of dierent cells, little is known about the role of NF-kB factors in the regulation of keratinocyte cell cycle. However, the ®nding that IkB-a de®cient mice exhibited severe dermatitis accompanied by strong epidermal hyperplasia and hyperkeratosis (Beg et al., 1995; Klement et al., 1996) strongly suggests that NF-kB promotes keratinocyte proliferation. Moreover, the skin phenotype in mice lacking both IkB-a and p50 subunit of NF-kB developed with dramatic delay in comparison with IkB-a 7/7 mice (Beg et al., 1995) . This partial rescue of the phenotype by the lack of p50 indirectly indicates that p50 is speci®cally important for NF-kB-mediated regulation of keratinocyte proliferation. These data are in agreement with our data on p50 overexpression in skin tumors. On the other hand, it has been recently proposed that, in contrast to the other tissues, p50 could inhibit cell proliferation in epidermis (Seitz et al., 1998) . These data obtained in transgenic mouse and human epidermis are not in line with our ®ndings on p50 overexpression during skin hyperplasia (data not shown) and in skin tumors. It is important that Seitz et al. (1998) used in their experiments constitutively active p50 mutant constantly expressed in nuclei of keratinocytes, thus generating transgenic epidermis with abnormal subcellular p50 localization.
As we have already mentioned various IkB proteins have distinct speci®city for the interaction with dierent NF-kB dimers (Baldwin, 1996; Matthews and Hay, 1995) . We found a modest decrease in the level of IkB-a expression in late papillomas and SCC. However, IkB-a anity to p50/p50 homodimers is low (Baldwin, 1996; Matthews and Hay, 1995; Whiteside and Israel, 1997) . The IkB proteins speci®cally interacting with p50/p50 dimers are p105, IkB-g identical to the C-terminal domain of p105, and Bcl-3 (Hatada et al., 1992; Inoue et al., 1992; Matthews and Hay, 1995; Watanabe et al., 1993) . Our experiments revealed that the expression of Bcl-3 is strongly increased in late mouse skin papillomas and SCC. These data could provide an explanation for the selective increase of p50-related kB-binding in mouse skin tumors. While Bcl-3 contains ankyrin repeats and is structurally similar to other IkB proteins, its function is remarkably dierent from other IkB proteins. Bcl-3 is usually present in the nuclei of cells and depending on experimental system, plays dierent roles aecting biological activities of p50 and p52 (Caamano et al., 1996) . Bcl-3 was demonstrated to be physically associated with p50 and p52 homodimers (Bours et al., 1993; Franzoso et al., 1993) . Most of the studies suggest that Bcl-3 is able to remove p50/p50 and p52/p52 homodimers from DNA allowing more potent NF-kB factors to interact with kB sites and activate transcription (Franzoso et al., 1992; Hatada et al., 1992; Inoue et al., 1993; Leveillard and Verma, 1993; Naumann et al., 1993; Nolan et al., 1993) . However, in other systems Bcl-3 worked as a transcriptional coactivator associated with p50 and p52 homodimers Fujita et al., 1993) . Bcl-3 interaction with p52 and p50 dimers strongly depends on its phosphorylation status . Experiments with 1ck.Bcl-3 thymusspeci®c transgenic mice indicated that constitutive expression of phosphorylated Bcl-3 dramatically increased p50/p50 binding but not p52/p52 binding to dierent kB sites (Caamano et al., 1996) . As we have already mentioned Bcl-3 protein was overexpressed in skin tumors. We also found that Bcl-3 was heavily phosphorylated in both normal and transformed keratinocytes. This suggests that Bcl-3 could augment p50/p50-related NF-kB binding in mouse keratinocytes in vivo. It has been shown recently that changes in phosphorylation of p50 are also very important for regulation of kB-binding activity in mouse skin (Perez et al., submitted) . Thus, we can not rule out the possibility that the level of phosphorylation of other NF-kB/IkB proteins, especially p50 itself, may aect kB binding in mouse skin tumors.
Interestingly, in thymocytes of Bcl-3 transgenic mice, association of Bcl-3 with p52 did not aect p52 anity to kB sites (Caamano et al., 1996) . The results of our preliminary experiments (data not shown) indicate that there was no change in p52-related kB-binding during carcinogenesis in spite of the observation that both p52 and Bcl-3 were overexpressed in tumors. We are currently investigating the expression of additional IkB proteins in mouse skin tumors to understand what proteins blocked p52 functional activity in transformed keratinocytes.
Our data showed conclusively that the expression of dierent NF-kB/IkB factors as well as kB-binding are strongly altered in both benign and malignant skin tumors. The unbalanced expression of various NF-kB/ IkB factors in transformed keratinocytes should have profound biological consequences because it directly aects the function of NF-kB factors and de®nes the set of kB-responsive genes under transcription. Thus, our results strongly suggest that NF-kB factors play an important role in skin carcinogenesis.
Materials and methods
SENCAR mouse skin two-stage carcinogenesis
Dorsal skins of female SENCAR mice (NCI, Frederick Cancer Research Facility, Frederick, MD, USA) in the resting stage of the hair cycle (8 ± 10 weeks of age) were shaved and initiated 3 days later with 7,12-dimethylbenz(a)anthracene (DMBA) (2.5 mg/mouse in 200 ml of acetone). Promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) (2 mg/mouse, twice a week) was started 2 weeks after initiation and continued for 50 weeks. Tumors were harvested 10 ± 50 weeks after initiation and frozen in liquid nitrogen.
Protein extracts
For whole-cell extracts mouse skin and skin tumors were ground on dry ice in buer C (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 25% glycerol) containing DTT and protease inhibitors. After three cycles of freezing and thawing, NP40 (1% ®nal concentration) was added to the samples and proteins were extracted by vigorous shaking of the samples on ice for 15 min. The samples were spun at 10 000 r.p.m. for 20 min at 48C, and the supernatant was used as whole-cell protein extract.
Cytoplasmic and nuclear extracts from frozen mouse skin and tumors were prepared as described by Schreiber et al. (1989) with some modi®cations. Tissues were ground on dry ice in buer A (10 mM HEPES, pH 7.9; 10 mM KCl, 0.1 mM EDTA, and 0.1 mM EGTA) containing DTT and protease inhibitors. Cytosolic proteins were extracted by shaking samples on ice for 15 min and separated by brief centrifugation at 2000 r.p.m. To isolate nuclear proteins, the pellet was resuspended in hypertonic buer C (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 25% glycerol) with DTT and protease inhibitors. Nuclear proteins were extracted by shaking samples vigorously on ice for 15 min and separated by centrifugation at 4000 r.p.m. for 5 min. The supernatant was used as nuclear protein extract.
Antibodies
Polyclonal antibodies raised against the synthetic peptides corresponding to amino acids 338 ± 357 mapping at the carboxy terminus of p50 of mouse origin; to amino acids 350 ± 363 mapping at the nuclear localization sequence of p50 of mouse origin; to amino acids 298 ± 324 mapping within a conserved epitope of p52 of mouse origin; to amino acids 531 ± 550 mapping at the carboxy terminus of p65 of mouse origin, to amino acids 297 ± 317 mapping at the carboxy terminus of IkB-a of mouse origin, and to the carboxy terminus of Bcl-3 of mouse origin were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). We also used polyclonal anti-p50 antibody raised against the epitope corresponding to amino acids 324 ± 452 of mouse p50 kindly provided by Drs R-P Ryseck and R Bravo (Bristol-Myers Squibb Pharmaceutical Institute, Princeton, NJ, USA). According to the manufacturer information and scienti®c publications, these NFkB antibodies are speci®c and not cross-reactive with other members of the NFkB/Rel family.
Western blotting
Whole-cell proteins, cytosolic and nuclear extracts from mouse skin and mouse skin tumors were resolved in SDS ± PAGE gels and transferred to nitrocellulose. Membranes were blocked with 5% non-fat milk in PBS, incubated with rabbit or goat polyclonal anti-p50, anti-p52, anti-p65 and anti-IkB-a antibodies for 2 h and with peroxidase-conjugated anti-rabbit or anti-goat IgG (Sigma St. Louis, MO, USA) for 1 h. ECL Western blotting detection kit (Amersham, IL, USA) was used to detect bands. The membranes were also stained with India ink to verify that equal amounts of protein were loaded and transferred.
Immuno¯uorescence
Immuno¯uorescent localization of p50, p52, p65 and IkB-a was evaluated in cryosections of SENCAR mouse skin and tumors. For p65, p52, and IkB-a immunostaining the cryosections were ®xed with cold acetone for 5 min and blocked for 2 h in 5% nonfat milk in PBS. For p50 immunostaining, the cryosections were ®xed with 4% paraformaldehyde followed by incubation with 10 mM glycine to quench aldehyde groups. After membrane permeabilization using 1% NP-40, sections were blocked in 1% bovine serum albumin. Then, sections were incubated with primary antibodies for 2 h. Antibody binding was visualized using an FITC-conjugated goat anti-rabbit IgG (Sigma, St. Louis, MO, USA).
Electrophoretic mobility shift assay (EMSA)
Whole-cell and nuclear protein extracts were prepared from intact SENCAR mouse epidermis and from mouse skin tumors. For EMSA, 15 mg of whole-cell protein extract, or 3 mg of nuclear extract, were incubated with a labeled oligonucleotide probe containing a palindromic kB binding site (Dobrzanski et al., 1993) in the reaction buer containing 20 mM HEPES (pH 7.9), 60 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 0.5 mM PMSF, 17% glycerol. DNA-protein complexes were separated by electrophoresis on 5.5% native polyacrylamide gels in 0.256 Trisborate-EDTA, dried and exposed to ®lm. For supershift assays, nuclear extracts were incubated with the indicated antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or preimmune serum (P.I.) 15 min prior to adding the labeled kB-oligonucleotide.
Northern blotting
Total RNA from freshly harvested mouse epidermis and frozen tumors was isolated by the guanidine isothiocyanatephenol-chloroform extraction. Northern blots containing total RNA (10 mg/lane) were probed for expression of nfkb1 and ikb-a. DNA probes were prepared by random primed reactions using the complete coding sequences of these transcription factors as templates. Plasmid with nf-kb1 cDNA was purchased from American Type Culture Collection (Rockville, MD, USA). ikb-a cDNA was a kind gift from Dr S Okret (Karolinska Institutet, Sweden). The membranes were also hybridized with a 7S RNA probe (Balmain et al., 1982) to verify that equal amounts of RNA were loaded and transferred. The amounts of mRNA were quanti®ed with a Bio Image Visage 60 scanning densitometer (Bio Image Products, Millipore Corp., Ann Arbor, MI, USA) and normalized to the amounts of 7S mRNA.
Abbreviations DMBA, 7,12-dimethylbenz(a)anthracene; SCC, squamous cell carcinoma; TPA, 12-O-tetradecanoyl-phorbol-13-acetate.
